All In MedTech

Device Trial Radar · NCT07571733

Study on the Efficacy of Spinal Cord Stimulation in Patients With Severe Refractory Primary or Secondary RLS

A Double-Blind, Randomized, Sham-Controlled, Crossover Study on the Efficacy of Burst Spinal Cord Stimulation in Patients With Severe Refractory Primary or Secondary RLS: the REST-SCS Study

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Feb 14, 2029

Study completion Feb 14, 2029

Sponsor

Lead sponsor
Clinica ARS MedicaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 6, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Double-Blind Randomized Controlled Crossover Study to compare the short-efficacy of Burst-SCS with Sham Stimulation, in patients with severe to very severe RLS refractory or intolerant to standard available treatments and/or patients in augmentation, with a two-period-alternating treatment design.

Conditions

  • Restless Leg Syndrome (RLS)

Interventions

  • Spinal cord stimulation (SCS)Device

    Burst SCS, a specific spinal cord stimulation waveform that delivers pulses in clusters separated by brief periods without stimulation, is chosen over other modalities due to its demonstrated ability to modulate both the sensory and affective components of pain and discomfort. Unlike traditional tonic stimulation, Burst SCS delivers stimulation patterns that more closely resemble natural neuronal firing, and may provide effective symptom relief without inducing paresthesia.

  • Sham stimulationDevice

    For the Sham stimulation condition, the amplitude of the spinal cord stimulation will be set to zero.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RLS symptom severityTime frame: From baseline of the treatment phase to the end of the 2.5 months treatment phase

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinica Ars Medica

    Gravesano, Canton Ticino, Switzerland

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.